Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenovirus
Researchers from McMaster University detail findings in adenovirus
March 31st, 2009
A new study, 'High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome,' is now available. According to a study from Canada, "We have investigated the therapeutic potential of a prototypic melanoma vaccine based on recombinant adenovirus expressing human dopachrome tautomerase in the B16F10 murine melanoma model. We found that in the presence of a tumor, the magnitude of T-cell immunity evoked by the vaccine was significantly reduced." "This impairment was compounded by defects in cytokine production and degranulation within the tumor-infiltrating lymphocytes (TILs). We showed that the combination of...
Source: Cancer Weekly (2009-03-31)
|
